Style | Citing Format |
---|---|
MLA | Sayedtabatabaei L, et al.. "Camouflaged Liposomes by 11A4-Nanobody for Co-Delivery of Cisplatin and Nitroxoline in Breast Cancer Tumors: An in Vitro/In Vivo Study." Journal of Drug Delivery Science and Technology, vol. 71, no. , 2022, pp. -. |
APA | Sayedtabatabaei L, Varshosaz J, Haghjooy Javanmard S, Soghrati S (2022). Camouflaged Liposomes by 11A4-Nanobody for Co-Delivery of Cisplatin and Nitroxoline in Breast Cancer Tumors: An in Vitro/In Vivo Study. Journal of Drug Delivery Science and Technology, 71(), -. |
Chicago | Sayedtabatabaei L, Varshosaz J, Haghjooy Javanmard S, Soghrati S. "Camouflaged Liposomes by 11A4-Nanobody for Co-Delivery of Cisplatin and Nitroxoline in Breast Cancer Tumors: An in Vitro/In Vivo Study." Journal of Drug Delivery Science and Technology 71, no. (2022): -. |
Harvard | Sayedtabatabaei L et al. (2022) 'Camouflaged Liposomes by 11A4-Nanobody for Co-Delivery of Cisplatin and Nitroxoline in Breast Cancer Tumors: An in Vitro/In Vivo Study', Journal of Drug Delivery Science and Technology, 71(), pp. -. |
Vancouver | Sayedtabatabaei L, Varshosaz J, Haghjooy Javanmard S, Soghrati S. Camouflaged Liposomes by 11A4-Nanobody for Co-Delivery of Cisplatin and Nitroxoline in Breast Cancer Tumors: An in Vitro/In Vivo Study. Journal of Drug Delivery Science and Technology. 2022;71():-. |
BibTex | @article{ author = {Sayedtabatabaei L and Varshosaz J and Haghjooy Javanmard S and Soghrati S}, title = {Camouflaged Liposomes by 11A4-Nanobody for Co-Delivery of Cisplatin and Nitroxoline in Breast Cancer Tumors: An in Vitro/In Vivo Study}, journal = {Journal of Drug Delivery Science and Technology}, volume = {71}, number = {}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Sayedtabatabaei L AU - Varshosaz J AU - Haghjooy Javanmard S AU - Soghrati S TI - Camouflaged Liposomes by 11A4-Nanobody for Co-Delivery of Cisplatin and Nitroxoline in Breast Cancer Tumors: An in Vitro/In Vivo Study JO - Journal of Drug Delivery Science and Technology VL - 71 IS - SP - EP - PY - 2022 ER - |